Article

Insights from a rare myeloproliferative neoplasm with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations treated with nilotinib and ruxolitinib

2022-01-20

Abstract excerpt

Myeloproliferative neoplasms (MPNs) with concurrent BCR-ABL1 fusion gene and CALR mutation are especially rare.We report a patient with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations who was treated with the combination of the second-generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 614b1990-3a8c-576a-a93d-c6ae7c6ad099
DOI: 10.22541/au.164269985.57864229/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 9 closest

Insights from a rare myeloproliferative neoplasm with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations treated with nilotinib and ruxolitinibDOI 10.22541/au.164269985.57864229/v1Read

A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.Semantic proximity Read

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?Semantic proximity Read

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.Semantic proximity Read

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.Semantic proximity Read

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesSemantic proximity Read

Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.Semantic proximity Read

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation.Semantic proximity Read

Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review.Semantic proximity Read

Post-HSCT maintenance treatment using entrectinib for an AML patient accompanied ETV6-NTRK3: a case reportSemantic proximity Read